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Introduction {#sec1}
============

The immune system protects the host from infectious diseases and helps to remove its damaged components. Its activity is controlled by stimulatory and inhibitory forces. Inhibitory pathways are important to prevent its spontaneous hyperactivation and to regulate established immune reactions.

B lymphocytes have emerged as important players in the negative regulation of immunity via the production of interleukin-10 (IL-10) and IL-35 ([@bib11], [@bib29]). This B cell function has noticeable effects in autoimmune, allergic, infectious, and malignant diseases ([@bib29]). The phenomenology of B cell-mediated suppression is well established, yet the B cells mediating these activities *in vivo* remain incompletely defined. Their identification has been approached by isolating known B cell subsets and assessing their capacity to produce IL-10 *in vitro* and to suppress immunity in recipient mice upon adoptive transfer. B cells expressing high amounts of CD1d, including marginal zone B cells and transitional T2-like B cells, as well as B1a cells and Tim-1^hi^ B cells, have the capacity to suppress immunity in an IL-10-dependent manner in such assays ([@bib3], [@bib37], [@bib38]). However, only a fraction of the cells within these subsets express IL-10 after activation *in vitro*, even when strong pharmacological agents such as ionomycin and phorbol myristate acetate (PMA) are used, and the phenotype of the B cells actually producing IL-10 *in vivo* in the recipient is not defined after transfer. Other studies have used IL-10 reporter mice to identify IL-10-producing cells *ex vivo* without re-stimulation. These have revealed CD138^hi^ plasmocytes (plasmablasts and plasma cells) as the major source of B cell-derived IL-10 *in vivo* in autoimmune, infectious, and malignant diseases ([@bib19], [@bib22], [@bib27], [@bib30], [@bib31]). A hypothesis reconciling these findings could be that B cell-mediated regulation is an inducible function acquired by B cells such as CD1d^hi^ B cells upon activation and differentiation into IL-10- or IL-35-producing plasmocytes.

Here, we addressed whether IL-10-producing plasmocytes defined a separate subset using a model of infection by the bacterium *Salmonella* Typhimurium. In this model, B cell-derived IL-10 is produced exclusively by plasmocytes that emerge before day 1 post-infection (p.i.) and leads to a rapid modulation of immunity to *Salmonella* ([@bib22]). We reasoned that the rapidity of this response would facilitate the identification of the precursors of immunosuppressive IL-10-producing plasmocytes without having to recourse to adoptive transfer protocols susceptible to creating non-physiological cellular responses.

Results {#sec2}
=======

LAG-3 Identifies IL-10-Expressing Plasma Cells in Infected Mice {#sec2.1}
---------------------------------------------------------------

*Salmonella* infection results in the rapid appearance of IL-10^+^CD138^hi^ cells. To assess whether these cells defined a particular subset, we compared their transcriptome to the one of IL-10^−^CD138^hi^ cells from *Il10*eGFP mice on day 1 p.i. This yielded 22 genes coding for transmembrane receptors overexpressed in IL-10^+^ cells ([Figure 1](#fig1){ref-type="fig"}A), including lymphocyte-activation gene 3 (*Lag3*; CD223) that was previously identified as a marker for IL-10-producing T regulatory type (Tr1) cells ([@bib13]).Figure 1LAG-3 Identifies IL-10-Producing Plasma Cells in Infected MiceMice were infected i.v. with *Salmonella* (SL7207, 10^7^ CFU), and plasmocytes characterized in spleen on day 1 p.i.(A) mRNA amounts for receptors overexpressed in IL-10^+^ compared with IL-10^−^ plasmocytes from *Il10*eGFP mice. Microarrays in triplicate. Expression amounts normalized using GCRMA are shown (Log2 transformed). *Lag3* is expressed 9.4-fold higher in *Il10*eGFP^+^CD138^hi^ than *Il10*eGFP^−^CD138^hi^ cells.(B) Flow cytometry plots showing IL-10 and LAG-3 expression in CD138^hi^ cells (left); frequency of LAG-3^+^ in IL-10^+^CD138^hi^ cells (middle); expression of IL-10 in B cells (CD19^+^CD138^−^) and LAG-3^+^CD138^hi^ cells (right). Representative of six experiments.(C) *Il10* mRNA expression in isolated subsets from C57BL/6 mice. Pool of two experiments.(D) Transmission electron microscopy images of plasmocytes from *Il10*eGFP mice. Scale bar is 2 μM.(E) Frequencies of antibody-secreting cells (ASCs) in IL-10^+^CD138^hi^ and IL-10^−^CD138^hi^ cells from *Il10*eGFP mice by ELISPOT. Pool of three experiments.(F) Flow cytometry plots of LAG-3 and Ki67 expression in CD138^hi^ cells from C57BL/6 mice. Representative of four experiments.(G) Flow cytometry plot of LAG-3 and BLIMP-1 in BLIMP-1^+^CD138^hi^ cells (left), and amounts of BLIMP-1 (MFI) in B cells and plasmocytes in *Prdm1*eGFP mice (n = 4) (right). Representative of two experiments.(H) Surface molecules expression on LAG-3^+^CD138^hi^ (red), LAG-3^−^CD138^hi^ (blue), and CD19^+^CD138^−^ B cells (gray) from C57BL/6 mice. Representative of two experiments.Data show mean ± SEM (^ns^p \> 0.05, ^∗∗^p \< 0.01). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

LAG-3 protein was found on most IL-10^+^CD138^hi^ cells on day 1 p.i., and IL-10 was expressed uniformly in LAG-3^+^CD138^hi^ cells ([Figure 1](#fig1){ref-type="fig"}B). LAG-3 was not detected on CD19^+^CD138^−^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This staining was specific because it was not observed on *Lag3*^*−/−*^ plasma cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Consistently, *Il10* mRNA was predominantly expressed in LAG-3^+^CD138^hi^ cells compared to other B cell subsets in infected C57BL/6 mice ([Figure 1](#fig1){ref-type="fig"}C).

IL-10^+^LAG-3^+^CD138^hi^ cells displayed typical plasma cell features including a plasmacytoid morphology ([Figure 1](#fig1){ref-type="fig"}D), the spontaneous secretion of antibodies ([Figure 1](#fig1){ref-type="fig"}E), a non-proliferative state ([Figure 1](#fig1){ref-type="fig"}F), and an elevated expression of BLIMP-1 ([Figure 1](#fig1){ref-type="fig"}G). LAG-3^+^CD138^hi^ cells also differed from LAG-3^−^CD138^hi^ cells in their higher expression of CD1d and CD200, as well as their lower expression of B220, MHC-II, CD43, CD71, and Fas ([Figure 1](#fig1){ref-type="fig"}H).

We conclude that LAG-3^+^CD138^hi^ plasma cells define the main population of IL-10-expressing B cells in infected mice.

LAG-3^+^CD138^hi^ Plasma Cells Develop Independently of Microbe-Derived Signals in Naive Mice {#sec2.2}
---------------------------------------------------------------------------------------------

The non-proliferating status of IL-10^+^LAG-3^+^CD138^hi^ cells was unexpected because B cell differentiation into plasma cell normally requires cell proliferation over several days. This led us to hypothesize that LAG-3^+^CD138^hi^ cells were already present in naive mice. Indeed, LAG-3^+^CD138^hi^ cells were detected in the spleen, bone marrow (BM), and mesenteric lymph nodes (mLN) of naive mice ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). They had the key attributes of plasma cells such as high BLIMP-1 expression ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}B), a plasmacytoïd morphology ([Figure 2](#fig2){ref-type="fig"}C), and the spontaneous secretion of antibodies ([Figure 2](#fig2){ref-type="fig"}D). In contrast to proliferating LAG-3^−^CD138^hi^ plasmablasts, LAG-3^+^CD138^hi^ cells were non-proliferative and produced mostly IgM ([Figures 2](#fig2){ref-type="fig"}D and 2E). These features of LAG-3^+^CD138^hi^ cells therefore did not change between day 0 and day 1 p.i., except for the induction of IL-10 expression after challenge ([Figure 2](#fig2){ref-type="fig"}F). LAG-3^+^CD138^hi^ cells also differed from LAG-3^−^CD138^hi^ cells in their higher expression of CD1d, CD69, CD81, CD200, and CD273 (PD-L2), as well as their lower expression of B220, MHC-II, CD43, CD71, FAS, and CXCR3 in naive mice ([Figure 2](#fig2){ref-type="fig"}G). PD-L1 was highly expressed by both plasmocyte subsets. LAG-3^+^CD138^hi^ cells expressed surface IgM, CD79α, and CD79β ([Figure 2](#fig2){ref-type="fig"}G). LAG-3 expression was not observed on B cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C).Figure 2LAG-3^+^CD138^hi^ Plasma Cells Are Present in Naive MiceAnalyses performed in spleen (except when indicated) of naive mice.(A) Flow cytometry plots of LAG-3 on CD138^+/hi^ cells (top) and frequencies in spleen (n = 23), BM (n = 19), mLN (n = 10), subcutaneous LN (sLN) (n = 10), and PeC (n = 10) (bottom) of C57BL/6 mice.(B) Flow cytometry plots of LAG-3 and BLIMP-1 in BLIMP-1^+^CD138^hi^ cells (left), and amounts of BLIMP-1 (MFI) in B cells and plasmocytes in *Prdm1*eGFP mice (n = 4) (right). Representative of three experiments.(C) Electron microscopy images of plasmocytes from C57BL/6 mice. Scale bar is 2 μM.(D) ASCs in plasmocytes from C57BL/6 mice by ELISPOT. Pool of two experiments.(E) Flow cytometry plot of LAG-3 and Ki67 in CD138^hi^ cells from C57BL/6 mice. Representative of four experiments.(F) Flow cytometry plot of LAG-3 and IL-10 in CD138^hi^ cells. Representative of six experiments.(G) Expression of indicated molecules on cells from C57BL/6 mice. Representative of 3--4 experiments.(H) Numbers of plasmocytes in SPF (n = 8) and GF (n = 8) C3H/HeOuJ mice.(I) Numbers and frequencies of plasmocytes in C57BL/6 mice of indicated ages (n = 6/age, pool of 2 experiments).Data show mean ± SEM (^ns^p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Plasma cells are normally induced upon foreign antigen stimulation. LAG-3^+^CD138^hi^ cells, however, were present in similar numbers in germ-free and specific-pathogen-free mice ([Figure 2](#fig2){ref-type="fig"}H). These cells are therefore generated via an endogenous response. Their number increased markedly in aging mice ([Figures 2](#fig2){ref-type="fig"}I and [S2](#mmc1){ref-type="supplementary-material"}D).

We conclude that, in naive mice, LAG-3^+^CD138^hi^ cells are a subset of natural plasma cells mainly producing IgM.

LAG-3^+^CD138^hi^ Cells Rapidly Upregulate IL-10 after Infection {#sec2.3}
----------------------------------------------------------------

IL-10 expression in CD138^hi^ cells increased already at 3 hr p.i. compared to naive mice (p = 0.0009; unpaired t test) ([Figure 3](#fig3){ref-type="fig"}A). IL-10 was expressed predominantly in LAG-3^+^CD138^hi^ cells during the first 24 hr p.i. ([Figure 3](#fig3){ref-type="fig"}A). IL-10 is thus programmed for a rapid expression in LAG-3^+^CD138^hi^ cells, whose numbers were similar at day 0 and day 1 p.i. ([Figure 3](#fig3){ref-type="fig"}B). As expected, IL-10 and LAG-3 were not detected in CD19^+^CD138^−^ B cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A).Figure 3LAG-3^+^CD138^hi^ Cells Upregulate IL-10 Expression upon InfectionAnalyses performed in spleen p.i. (SL7207, 10^7^ CFU) or with naive mice.(A) Kinetics of IL-10 expression in CD138^hi^ cells (left), frequency of LAG-3^+^ in IL-10^+^CD138^hi^ cells (middle), numbers of LAG-3^+^IL-10^+^CD138^hi^ (LAG-3^+^) and LAG-3^−^IL-10^+^CD138^hi^ (LAG-3^−^) cells (right) p.i. in *Il10*eGFP mice. Pool of two experiments (n = 6/time point).(B) Numbers of LAG-3^+^CD138^hi^ cells in C57BL/6 mice. Pool of four experiments (n = 11/time point).(C) Isolated cells from naive C57BL/6 mice were stimulated *in vitro* for 18 hr, and IL-10 measured in supernatants. LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ cells indicated as LAG-3^+^ and LAG-3^−^, respectively. Pool of five experiments.(D) Numbers of CD138^hi^ and LAG-3^−^CD138^hi^ cells (left), LAG-3^+^IL-10^+^CD138^hi^ cells (middle), frequency of LAG-3^+^ (red line) or IL-10^+^ (green line) cells in CD138^hi^ cells (right) p.i. in *Il10*eGFP mice. Pool of 4 experiments; at least 12 mice per group.(E) Numbers of IL-10^+^CD138^hi^ and IL-10^−^CD138^hi^ cells at day 3 p.i. in B-*Il10*eGFP and B-*Lag3*^−/−^*Il10*eGFP chimeric mice.(F) *Il10*eGFP mice were vaccinated and challenged 90 days later (vaccinated), along with age-matched naive *Il10*eGFP mice (challenged). Frequencies of LAG-3^+^ in CD138^hi^ cells (left), and of IL-10^+^ in CD138^hi^ cells (right). Pool of two experiments; at least six mice per group.(G) *Il10*eGFP mice treated as in (F) and analyzed at day 1 and 2 post-re-challenge. Flow cytometry plots show LAG-3 and CD138 on IL-10^+^CD138^hi^ cells (right, day 1) with quantifications (left). Pool of two experiments; at least six mice per group.(H) *Il10*eGFP mice were treated as in (F). Frequency of ASC in indicated plasmocytes on day 1 post-re-challenge by ELISPOT. Pool of two experiments; at least six mice per group.Data shown are mean ± SEM (^ns^p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

The immediate upregulation of IL-10 in LAG-3^+^CD138^hi^ cells led us to compare the capacity of CD138^hi^ cells and other B cell subsets to produce IL-10 *in vitro*. CD138^hi^ plasmocytes secreted markedly more IL-10 than CD1d^hi^CD19^+^ B cells ([Figure 3](#fig3){ref-type="fig"}C), and their IL-10 production derived mostly from LAG-3^+^CD138^hi^ cells ([Figure 3](#fig3){ref-type="fig"}C).

We then examined IL-10 expression at later time points p.i. during the extra-follicular response. The number of CD138^hi^ cells increased progressively p.i., and they represented 10% of all splenocytes on day 8 p.i. ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B). This increase reflected the accumulation of LAG-3^−^CD138^hi^ cells, while IL-10^+^LAG-3^+^CD138^hi^ cells did not expand greatly after day 1 p.i. ([Figure 3](#fig3){ref-type="fig"}D). IL-10 expression was associated with LAG-3^+^CD138^hi^ cells at all time points ([Figure S3](#mmc1){ref-type="supplementary-material"}C). The frequencies of LAG-3^+^ and IL-10^+^ cells within CD138^hi^ cells sharply decreased from day 1 p.i. onward ([Figure 3](#fig3){ref-type="fig"}D). These results emphasize the unique response dynamics of IL-10^+^LAG-3^+^CD138^hi^ cells. Because LAG-3 has been implicated in the regulation of humoral immunity ([@bib4]), we asked whether LAG-3 expressed on CD138^hi^ cells modulated the plasmocyte response p.i. To this end, we crossed *Lag3*^−/−^ mice on an *Il10*eGFP background and generated mixed bone marrow chimera in which only B cells lacked *Lag3* but could express *Il10*eGFP. A LAG-3 deficiency in plasma cells did not alter the number of IL-10^+^CD138^hi^ cells p.i., yet led to an increased accumulation of IL-10^−^CD138^hi^ cells ([Figure 3](#fig3){ref-type="fig"}E). Thus, LAG-3^+^CD138^hi^ cells control the expansion of LAG-3^−^CD138^hi^ cells in a LAG-3-dependent manner.

An important property of the adaptive immune system is immunological memory. To assess whether LAG-3^+^CD138^hi^ cells acquire features of memory B cells, we compared their response in vaccinated and naive mice p.i. As expected, vaccinated mice better controlled *Salmonella* than naive mice ([Figure S3](#mmc1){ref-type="supplementary-material"}D). IL-10 and LAG-3 expression in CD138^hi^ cells were comparable in the two groups p.i. ([Figures 3](#fig3){ref-type="fig"}F and 3G). Thus, LAG-3^+^CD138^hi^ cells did not display the typical sign of an amplified response upon rechallenge. IL-10^+^CD138^hi^ cells isolated from vaccinated mice on day 1 p.i. produced mostly IgM ([Figure 3](#fig3){ref-type="fig"}H), indicating that they had not undergone isotype switching away from IgM, unlike what is observed in classical memory B cell responses.

These data show that LAG-3^+^CD138^hi^ cells can rapidly upregulate IL-10 expression without dividing, and inhibit the expansion of LAG-3^−^CD138^hi^ cells p.i.

LAG-3^+^CD138^hi^ Cells Have a Unique Plasma Cell Epigenome {#sec2.4}
-----------------------------------------------------------

We next examined the hypothesis that LAG-3^+^CD138^hi^ cells were a distinct subset of plasma cells epigenetically poised to rapidly produce IL-10. To this end, we compared the genome-wide DNA-methylomes of LAG-3^+^CD138^hi^ cells, LAG-3^−^CD138^hi^ cells, and peripheral B cell subsets from naive mice. In addition, we included LAG-3^+^CD138^hi^, LAG-3^−^CD138^hi^, IL-10^+^CD138^hi^, and IL-10^−^CD138^hi^ cells isolated at day 1 p.i.

Genome-wide DNA-methylation profiling was performed by reduced representation bisulfite sequencing (RRBS) covering on average 3--4 million CpG sites per sample. An unsupervised principal component analysis (PCA) placed LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ cells at a distinctive position relative to LAG-3^−^CD138^hi^ and IL-10^−^CD138^hi^ cells, as well as to other B cell subsets, underlying their unique methylome profile. The position of LAG3^+^CD138^hi^ cells taken at day 0 and day 1 p.i. was similar and showed a striking co-localization with IL-10^+^CD138^hi^ cells ([Figure 4](#fig4){ref-type="fig"}A), underlining the intimate relationship between these subsets. The various groups of CD138^hi^ cells localized at the same position on PC1, which separated B cells from plasma cells. In keeping with the described hypomethylation of plasma cells' genome ([@bib17]), the various CD138^hi^ subsets analyzed here displayed the lowest degree of genome-wide methylation ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Thus, LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ cells have a plasma cell epigenetic profile but with unique features. A pairwise comparison of LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ cells from naive mice identified 469 differentially methylated regions (DMRs) showing a genome-wide distribution ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In a hierarchical analysis, these DMRs separated CD138^hi^ cells and B1 cells away from the other B cell subsets ([Figure 4](#fig4){ref-type="fig"}B), with LAG-3^+^CD138^hi^ cells showing the highest similarity to B1a cells ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}C). A particular cluster of DMRs was found at the *Il10* locus. IL-10^+^CD138^hi^ cells, LAG-3^+^CD138^hi^ cells, and B1a cells not only exhibited the lowest overall degree of DNA methylation at the *Il10* locus ([Figure 4](#fig4){ref-type="fig"}C) but also shared distinct patterns of hypomethylated regions around the *Il10* gene. Many of these hypomethylated sites overlapped with B cell-specific DNase hypersensitive sites, indicating an epigenetic "preprogrammed" open chromatin state of *Il10* in IL-10^+^CD138^hi^, LAG-3^+^CD138^hi^, and B1a cells ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}D). Of note, IL-10^+^CD138^hi^ cells, LAG-3^+^CD138^hi^ cells, and B1a cells also showed a preferential epigenetic relationship at the 469 DMR ([Figure S4](#mmc1){ref-type="supplementary-material"}E).Figure 4Molecular Characterization of LAG-3^+^CD138^hi^ Cells(A) Unsupervised PCA of genome-wide DNA methylation data of cells from C57BL/6 mice.(B) Methylation of the CpG found in the 469 DMR distinguishing LAG-3^+^CD138^hi^ cells and LAG-3^−^CD138^hi^ cells.(C) DNA methylation of *Il10* locus (mean ± SEM).(D) Methylation for covered CpG in the *Il10* locus. Coverage weighted average methylation of three replicates is represented. The positions of selected CpG are indicated by vertical black bars, with the *Il10* gene depicted. ENCODE DNase I data are in red for splenic CD43^−^ B cells. PhastCons Vert30 conservation scores are in blue.(E) mRNA expression for the 3,631 DEGs that distinguish LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ cells on day 0 and 1 p.i. (see [Figure S4](#mmc1){ref-type="supplementary-material"}F).(F) mRNA expression and local DNA methylation for genes both differentially expressed and methylated between LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ cells from naive mice.(G) Transcription regulators expressed at higher (top) or lower (bottom) amounts on both day 0 and 1 p.i. in LAG-3^+^CD138^hi^ compared to LAG-3^−^CD138^hi^ cells.(H) Expression of transcription regulators differentially expressed between LAG-3^+^CD138^hi^ cells and LAG-3^−^CD138^hi^ cells (see G) with predicted binding motif in either the *Il10*, *Lag3*, *Cd200*, or *Cd273* loci.Row z-scores for expression are based on log~10~(rpkm+1), and for DNA methylation on DNA methylation frequency (%).Samples were from naive mice (A, C, D, E, G, H) except where indicated. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

In summary, LAG-3^+^CD138^hi^ cells are the epigenetically primed precursors of IL-10^+^LAG-3^+^CD138^hi^ cells and show a distinct plasma cell-specific epigenome with the *Il10* locus primed for expression and features reminiscent of B1a cells.

Transcriptional Properties of LAG-3^+^CD138^hi^ Cells {#sec2.5}
-----------------------------------------------------

We next determined the transcriptomes of LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ cells on day 0 and day 1 p.i by mRNaseq. These analyses identified 648 differentially expressed genes (DEGs) (pval ≤ 0.01; FDR ≤ 0.05) on day 0 and 2,280 on day 1 p.i. ([Figure S4](#mmc1){ref-type="supplementary-material"}F). A hierarchical clustering with all DEGs confirmed the relative proximity of LAG-3^+^CD138^hi^ cells from naive mice and day 1 p.i. compared to LAG-3^−^CD138^hi^ cells ([Figure 4](#fig4){ref-type="fig"}E). The top DEGs ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}) included genes coding for IL-10 and the surface proteins LAG-3, CD200, and CXCR3, whose differential expression was also reflected in protein amount ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). A Gene Set Enrichment Analysis (MSigDB) of the 648 DEGs in naive mice highlighted cell cycle regulation as the major pathway discriminating the LAG3^−^ and LAG3^+^ subsets ([Figure S4](#mmc1){ref-type="supplementary-material"}G). 23 of the 648 DEGs were also differentially methylated between LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ cells, including *Il10*, *Bcl2*, *Zfp36l1*, *Irf8*, and other B cell regulators ([Figure 4](#fig4){ref-type="fig"}F). This argues for an epigenetically primed control of their expression.

We finally focused on transcription regulators differentially expressed in higher (or lower) amount on both day 0 and 1 p.i. in LAG-3^+^CD138^hi^ cells as compared to LAG-3^−^CD138^hi^ cells. We identified 22 factors (including transcription factors and co-factors, gene expression regulators, and general DNA binding proteins) with higher expression in LAG-3^+^CD138^hi^ cells and 8 factors with higher expression in LAG-3^−^CD138^hi^ cells ([Figure 4](#fig4){ref-type="fig"}G). LAG-3^+^CD138^hi^ cells showed a higher expression of *Klf4*, *Bhlhe40*, and *Bmyc* that are involved in the inhibition of proliferation, and of *Hes1* that indicates higher Notch signaling activity. They also displayed a higher expression of *Fos*, *Junb*, *Egr1*, *Egr2*, *Cebpb*, *Irf8*, and *Satb1* ([Figures 4](#fig4){ref-type="fig"}G and 4H), i.e., genes coding for factors for which we found predicted binding sites in the *Il10*, *Lag3*, *Cd200*, and *Cd273* (PD-L2) loci ([Figure 4](#fig4){ref-type="fig"}H). FOS, JUN-B, and EGR-2 drive IL-10 expression in other immune cells ([@bib16], [@bib34], [@bib39]). EGR2 was also important in CD4^+^ T cells for LAG-3 expression, BLIMP-1-mediated induction of IL-10, and their regulatory activity ([@bib16]). The reduced expression of *Foxm1* in LAG-3^+^CD138^hi^ cells ([Figures 4](#fig4){ref-type="fig"}G and 4H) might be linked to two effects: their lack of proliferation ([@bib5]) and the control of *Il10* transcription since Foxm1 binding sites were predicted in this locus ([Figure 4](#fig4){ref-type="fig"}H).

We conclude that LAG-3^+^CD138^hi^ cells exhibit a distinct transcriptome, partially linked to epigenetic changes, keeping them in a quiescent state primed for IL-10 expression. This molecular program could explain why only this subset of plasmocytes expresses IL-10 and other immune checkpoint receptor molecules.

BCR Repertoire and Developmental Origin of LAG-3^+^CD138^hi^ Cells {#sec2.6}
------------------------------------------------------------------

The differentiation of B cells into plasma cells requires the engagement of their BCR by antigen. Our observation that LAG-3^+^CD138^hi^ cells develop independently of the microbiota prompted us to examine whether they express a particular BCR repertoire.

Single-cell analysis of their IgH and Igk revealed that LAG-3^+^CD138^hi^ cells and IL-10^+^CD138^hi^ cells displayed a lower utilization of IgH VH1-81 and a higher usage of VH7, VH10, and VH11 segments compared to LAG-3^−^CD138^hi^ cells and IL-10^−^CD138^hi^ cells ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). The majority of VH11^+^ IgH were associated with a Vk14.126^+^ (formerly Vk9) Igk ([Figure 5](#fig5){ref-type="fig"}B), forming a combination typical of B1a cells ([@bib15]). Flow cytometry analyses confirmed the presence of a VH11^+^Vk14.126^+^ BCRs on splenic LAG-3^+^CD138^hi^ cells and IL-10^+^CD138^hi^ cells but not on LAG-3^−^CD138^hi^ cells or IL-10^−^CD138^hi^ cells ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}B). Of note, the BM from naive mice contained IL-10^+^CD138^hi^ cells ([Figure 5](#fig5){ref-type="fig"}D) enriched in VH11^+^Vk14.126^+^ cells ([Figure 5](#fig5){ref-type="fig"}E). Thus, some LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ cells carry a VH11^+^Vk14.126^+^ BCRs typical of B1a cells ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). However, the other VH segment classically associated with B1a cells, namely VH12, was not found in spleen LAG-3^+^CD138^hi^ cells, and only on about 1% of BM IL-10^+^CD138^hi^ cells ([Figure 5](#fig5){ref-type="fig"}F). The VH11^+^ IgH from LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ cells had few mutations as well as N-additions, and a large proportion contained the CDR3 characteristic of the anti-phosphatidylcholine (PtC) response ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). Accordingly, nearly all VH11^+^Vk14.126^+^ cells displayed reactivity against PtC ([Figure 5](#fig5){ref-type="fig"}G), and about 2% of splenic LAG-3^+^CD138^hi^ cells as well as 26% of BM IL-10^+^CD138^hi^ cells in naive mice reacted toward this particular antigen ([Figure 5](#fig5){ref-type="fig"}H). In BM, more than 80% of PtC-reactive CD138^hi^ cells expressed IL-10 ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Taken together, these data strongly suggest that VH11^+^Vk14.126^+^LAG-3^+^CD138^hi^ spleen and BM cells derive from B1a cells. Some LAG-3^+^CD138^hi^ cells expressing other BCR might also derive from B1a cells because LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ cells had overall fewer IgH somatic mutations than LAG-3^−^CD138^hi^ and IL-10^−^CD138^hi^ cells ([Figure 5](#fig5){ref-type="fig"}I). This correlated with a lower AID fate-mapping marking of LAG-3^+^CD138^hi^ cells ([Figure 5](#fig5){ref-type="fig"}J). Furthermore, a higher proportion of IgH from LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ lacked both somatic mutation and N-addition as compared to LAG-3^−^CD138^hi^ and IL-10^−^CD138^hi^ cells ([Figure 5](#fig5){ref-type="fig"}K). Nonetheless, some LAG-3^+^CD138^hi^ and IL-10^+^CD138^hi^ cells expressed IgH sequences with mutations and N-additions ([Figure 5](#fig5){ref-type="fig"}L), suggesting an additional origin for LAG-3^+^CD138^hi^ cells.Figure 5BCR Repertoire of LAG-3^+^ and IL-10^+^ Plasmocytes(A) Frequency of *Igh* containing VH1-81 (left) or VH11 (middle) in spleen LAG-3^+^CD138^hi^ (n = 253), LAG-3^−^CD138^hi^ (n = 150), *Il10*eGFP^+^CD138^hi^ (n = 181), and *Il10*eGFP^−^CD138^hi^ (n = 121) cells on day 0 and day 1 p.i. (SL7207; 10^7^ CFU). Frequency of LAG-3^+^ in VH11^+^CD138^hi^ and VH11^−^CD138^hi^ spleen cells of naive mice (n = 12) (right).(B) Frequency of Vk14.126^+^ cells in VH11^+^ cells for spleen and BM cells described in [Figure S5](#mmc1){ref-type="supplementary-material"}A.(C) Frequency of VH11^+^Vk14.126^+^ cells by flow cytometry. Pool of two experiments (6--7 mice/group/time point).(D) Flow cytometry plot of LAG-3 versus *Il10*eGFP in CD138^hi^ BM cells at day 1, and quantifications. Pool of four experiments (n = 12--17/time point).(E) Flow cytometry plot and frequency of VH11^+^Vk14.126^+^ cells in IL-10^+^CD138^hi^ cells in BM of *Il10*eGFP mice. Pool of two experiments (n = 6--7/time point).(F) Frequency of VH11^+^Vk14.126^+^ and VH12^+^ cells in B1a cells from indicated tissues (left), spleen LAG-3^+^ and LAG-3^−^ (middle), and BM IL-10^+^ and IL-10^−^ (right) plasmocytes from naive mice. Pool of two experiments (n = 7).(G) Frequency of PtC-reactive cells in VH11^+^Vk14.126^+^ cells for indicated cells from naive mice. Pool of two experiments (n = 7).(H) Frequency of PtC-reactive cells in indicated plasmocytes from naive mice. Pool of four experiments (n = 12).(I) Mutations in IgH sequences (naive BM *Il10*eGFP^+^CD138^hi^, n = 165; *Il10*eGFP^−^CD138^hi^, n = 151; naive spleen LAG-3^+^CD138^hi^, n = 231; LAG-3^−^CD138^hi^, n = 129; day 1 spleen *Il10*eGFP^+^CD138^hi^, n = 155; *Il10*eGFP^−^CD138^hi^, n = 108) (left). Number of somatic mutations per sequence for mutated IgH (LAG-3^+^CD138^hi^ cells, n = 31; LAG-3^−^CD138^hi^ cells, n = 19) (right).(J) *Aicda*-cre-ERT2-ROSA-STOP-RFP mice were treated with tamoxifen and analyzed 15 days after the last treatment. Frequency of RFP^+^ cells in LAG-3^+^CD138^hi^ and LAG-3^−^CD138^hi^ spleen cells. Pool of five experiments (n = 14).(K) Frequency of IgH sequences (as in I) having no mutation and no N-nucleotide addition.(L) Frequency of IgH sequences (as in I) with mutation and N-nucleotide addition.(M) Frequency of LAG-3^+^ in spleen CD138^hi^ cells 3 weeks after transfer of indicated cell fractions into *Rag2*^−/−^ mice. Pool of three experiments (n = 6--7/group).(N) Frequency of eYFP^−^ cells in indicated cells of naive *Cd21*-cre-ROSA-STOP-eYFP mice. Pool of three experiments (n = 6).Groups were compared using two-tailed unpaired t test with Welch's correction in case of inequal variances (C--I) or using Mann-Whitney test (M). Data are mean ± SEM (^ns^p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To evaluate the capacity of various B cell subsets to generate LAG-3^+^CD138^hi^ cells, we adoptively transferred B1a, B1b, and B2 cells from peritoneal cavity (PeC) as well as splenic B cells into *Rag2*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}M). The analysis of the recipient mice confirmed that several B cell subsets could give rise to LAG-3^+^CD138^hi^ cells, as observed also upon culture of B cell subsets *in vitro* ([Figure S5](#mmc1){ref-type="supplementary-material"}H). Marginal zone B cells were not a non-redundant source of LAG-3^+^CD138^hi^ cells *in vivo* since mice that lacked marginal zone B cells due to a B cell-restricted deficiency in NOTCH2 ([@bib25]) displayed normal frequency of LAG-3^+^CD138^hi^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}I) despite their globally reduced numbers of splenic plasmocytes (data not shown). To further delineate the origin of LAG-3^+^CD138^hi^ cells in a physiological context, we next developed a fate mapping system using the fact that B1a cells poorly expressed CD21 compared to other B cell susbsets, and crossed *Cd21*-cre mice to ROSA-STOP-eYFP reporter mice. In *Cd21*-cre-ROSA-STOP-eYFP mice, most B1a cells were eYFP^−^ in PeC, spleen, and BM, which was even more apparent when focusing on the VH11^+^Vk14^+^ fraction of B1a cells ([Figure 5](#fig5){ref-type="fig"}N). In contrast, B1b and B2 cells from PeC as well as follicular and marginal zone B cells from spleen were mostly eYFP^+^ ([Figure 5](#fig5){ref-type="fig"}N). The LAG-3^+^CD138^hi^ cell subset contained an intermediate frequency of eYFP^−^ cells, underlining their heterogeneous origin. Importantly, the LAG-3^+^CD138^hi^ cells that carried a VH11^+^Vk14^+^ BCR were largely eYFP^−^, indicating that eYFP^−^ B1a cells did not switch-on eYFP expression during their differentiation into LAG-3^+^CD138^hi^ cells ([Figure 5](#fig5){ref-type="fig"}N).

We conclude that LAG-3^+^CD138^hi^ cells develop from several B cell subsets via a mechanism involving the BCR since they have a distinct BCR repertoire.

Roles of BCR and TLR in LAG-3^+^CD138^hi^ Plasma Cell Development and Function {#sec2.7}
------------------------------------------------------------------------------

We next examined how the BCR influenced the accumulation of LAG-3^+^CD138^hi^ cells in naive mice and their upregulation of IL-10 after challenge.

The Bruton tyrosine kinase (Btk) is essential for BCR signaling ([@bib7]). *Btk*^−/−^ mice showed a developmental defect in B1a cells but not in B1b cells and marginal zone B cells ([Figure 6](#fig6){ref-type="fig"}A). They also displayed reduced frequencies and numbers of LAG-3^+^CD138^hi^ cells ([Figure 6](#fig6){ref-type="fig"}A). We next assessed the effect of the BCR co-receptors CD19 and CD72 for the generation of LAG-3^+^CD138^hi^ cells. We also studied mice genetically deficient in proteins involved in antigen presentation (CD1d), innate immune signaling (MyD88 and TRIF), T cell:B cell interaction (CD40, T cell receptor for antigen), and inflammation (NOS2, IL-10) ([Figure 6](#fig6){ref-type="fig"}B). LAG-3^+^CD138^hi^ cells were present in lower amounts in mice deficient for CD19, which is a positive regulator of BCR signaling, and in higher numbers in mice lacking CD72, which is an inhibitory BCR co-receptor. In contrast, they were normally present in *Myd88*^*−/−*^*Trif*^−/−^ mice, which lacked TLR signaling. Mice deficient in CD40 or αβTCR-expressing T cells also generated these cells normally. LAG-3^+^CD138^hi^ cells can therefore develop independently of canonical T cell:B cell interactions and are thus not strictly dependent on a T cell-dependent antigen. The finding that BCR but not TLR signaling contributed to the formation of LAG-3^+^CD138^hi^ cells led us to assess whether mice with a restricted BCR repertoire had an altered abundance of these plasma cells. Indeed, B1-8i mice carrying a fixed IgH chain on an Igk-deficient background displayed a 2-fold reduction in the frequency of LAG-3^+^CD138^hi^ cells compared to controls ([Figure 6](#fig6){ref-type="fig"}C). Of note, antibodies cloned from LAG-3^+^CD138^hi^ cells displayed little polyreactivity when tested as recombinant molecules in ELISA ([@bib33]), unlike those from BM IL-10^−^IgM^+^CD138^hi^ cells ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Considering that BCR signaling contributed to the development of LAG-3^+^CD138^hi^ cells at steady state, we next asked whether such cells could be generated upon immunization with 4-hydroxy-3-nitrophenylacetyl keyhole limpet hemocyanin (NP-KLH), NP-Ficoll, or NP-LPS i.e., classical T cell-dependent, T cell-independent type II, and T cell-independent type I antigens, respectively ([Figure S6](#mmc1){ref-type="supplementary-material"}B). These immunizations induced NP-reactive LAG-3^−^CD138^hi^ cells, but not NP-reactive LAG-3^+^CD138^hi^ cells. We conclude that LAG-3^+^CD138^hi^ cells develop from B cells at steady state upon a particular form of BCR engagement that is not recapitulated by these immunizations.Figure 6Molecules Implicated in the Homeostasis of LAG-3^+^CD138^hi^ Cells(A) Flow cytometry plots and quantification of indicated cells in PeC (top) and spleen (bottom) of naive *Btk*^−/−^ mice and littermate controls. Pool of two experiments (n = 6).(B) Numbers and frequencies of LAG-3^+^CD138^hi^ cells in CD138^hi^ plasmocytes in spleen of naive C57BL/6 (n = 40), *Cd19*^*−/−*^ (n = 5), *Il10*^*−/−*^ (n = 8), *Tcrab*^*−/−*^ (n = 7), *Cd72*^*−/−*^ (n = 10), *Cd1d*^*−/−*^ (n = 6), *Myd88*^*−/−*^ (n = 10), *Myd88*^*−/−*^*Trif*^*−/−*^ (n = 12), *Cd40*^*−/−*^ (n = 6), *Nos2*^*−/−*^ (n = 10), and *Fcgr2b*^*−/−*^ (n = 5) mice.(C) Frequencies of LAG-3^+^ in spleen CD138^hi^ cells of B1-8i*Igk*^−/−^ and WT mice. Pool of two experiments (n = 4--5).(D) Frequency of IL-10 in spleen LAG-3^+^CD138^hi^ of *Il10*eGFP mice 24 hr after i.v. injection of indicated reagents. Pool of three experiments (n = 6).Data show mean ± SEM (^ns^p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We next asked whether BCR or other signals controlled the upregulation of IL-10 expression in LAG-3^+^CD138^hi^ cells after challenge. To this end, *Il10*eGFP mice were injected intravenously with anti-BCR, anti-CD40, or LPS, alone or in combination ([Figure 6](#fig6){ref-type="fig"}D). The administration of anti-BCR or anti-CD40 had no effect on IL-10 expression, yet LPS induced a strong upregulation of IL-10 in LAG-3^+^CD138^hi^ cells. These results demonstrated that IL-10 expression was induced in a polyclonal manner in LAG-3^+^CD138^hi^ cells upon TLR4 stimulation. This was in agreement with the fact that LAG-3^+^CD138^hi^ cells from naive mice, as well as of LAG-3^+^CD138^hi^ cells and IL-10^+^CD138^hi^ cells from day 1 p.i., had comparable frequencies of VH11^+^Vk14^+^ cells ([Figure 5](#fig5){ref-type="fig"}C), suggesting that IL-10 was induced in LAG-3^+^CD138^hi^ cells in a polyclonal manner.

We conclude that the development of LAG-3^+^CD138^hi^ cells is controlled by the BCR and independent of TLR signaling as well as T cell help, while their upregulation of IL-10 after challenge is determined by TLR signaling.

Elevated Abundance of LAG-3^+^CD138^hi^ Cells Correlates with Impaired Immunity against *Salmonella* {#sec2.8}
----------------------------------------------------------------------------------------------------

An ablation of IL-10 production by CD138^hi^ plasmocytes increased host defense to *Salmonella* ([@bib22]). Here, we sought to determine how an increased abundance of LAG-3^+^CD138^hi^ cells affected host resistance to this infection using *Cd72*^*−/−*^ mice.

*Cd72*^*−/−*^ mice had an increased number of LAG-3^+^CD138^hi^ cells, while other B cell subsets did not display any major defect ([Figure S7](#mmc1){ref-type="supplementary-material"}A). The increased accumulation of LAG-3^+^CD138^hi^ cells in *Cd72*^−/−^ mutants was confirmed with littermate mice ([Figure S7](#mmc1){ref-type="supplementary-material"}A). After infection, *Cd72*^−/−^ mice displayed an increased accumulation of IL-10^+^CD138^hi^ and LAG-3^+^CD138^hi^ cells ([Figures 7](#fig7){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}B), an impaired control of the infection ([Figure S7](#mmc1){ref-type="supplementary-material"}C), and a reduced survival ([Figure 7](#fig7){ref-type="fig"}B) compared to controls. The CD72 deficiency had no effect in B cell-deficient mice, confirming that the observed differences were due to the lack of *Cd72* in B cells ([Figure S7](#mmc1){ref-type="supplementary-material"}D). To validate the inhibitory impact of IL-10 on host defense in *Cd72*^−/−^ mice, mice were treated intravenously with a combination of anti-IL-10 and anti-IL-10 receptor. This significantly improved the control of the bacteria ([Figure 7](#fig7){ref-type="fig"}C). Since LAG-3^+^CD138^hi^ cells are the major source of IL-10 after infection, this supports the notion that LAG-3^+^CD138^hi^ cells inhibit host defense through IL-10 provision.Figure 7CD72 Deficiency Enhances Susceptibility to *Salmonella*(A) Numbers of indicated spleen cells in *Il10*eGFP and *Cd72*^−/−^*Il10*eGFP mice p.i. (SL7207, 10^7^ CFU). Pool of three experiments (n = 9--12/time point/group).(B) Survival of *Cd72*^*−/−*^ (n = 16) and controls (n = 16) after infection (SL1344, 100 CFU). Pool of two experiments.(C) CFU on day 3 p.i. (SL7207, 10^7^ CFU) of anti-IL10 plus anti-IL10R-treated and control *Cd72*^−/−^ mice. Pool of two experiments (n = 6--10/group).(D) Mice were vaccinated (SL7207, 10^6^ CFU) and re-challenged on day 90 (SL7207, 10^7^ CFU). Numbers of cells in spleen after re-challenge. Pool of three experiments (n = 9/group/time point).(E) Mice were vaccinated (SL7207, 10^6^ CFU), rechallenged on day 90 (SL7207, 10^6^ CFU), and analyzed 5 days later with (+) or without (−) rechallenge. Pool of four experiments (n = 15--18/group/time point).(F) CFU on day 5 post-re-challenge for mice shown in (E) (left). Survival of *Cd72*^*−/−*^ (n = 17) and littermate control (n = 19) mice vaccinated (SL7207, 10^6^ CFU) and re-challenged 90 days later (SL1344, 100 CFU). Pool of two experiments (right).(G) *Cd72*^*−/−*^ and WT mice were vaccinated (SL7207, 10^6^ CFU), and BM analyzed on day 90. Flow cytometry plot (left) and quantifications (right) for CD40L, TNF-α, and IFN-γ expression in *Salmonella*-reactive memory CD4^+^ T cells. Pool of three experiments (n = 12).(H) Flow cytometry plots showing PD-1 and FOXP-3 in spleen CD4^+^ T cells of mice treated as in (E) and analyzed on day 0 and 5 post-rechallenge. Pool of three experiments (n = 12/group).Groups were compared using two-tailed unpaired t test (^ns^p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). Survival curves were compared using Wilcoxon test, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. Data show mean ± SEM. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Finally, we investigated how CD72 deficiency affected the host response to secondary infection. *Il10*eGFP and *Cd72*^−/−^*Il10*eGFP mice were vaccinated and later challenged with *Salmonella*. Mice lacking *Cd72* displayed a higher accumulation of IL-10^+^CD138^hi^ cells and LAG-3^+^CD138^hi^ cells upon re-challenge, while LAG-3^−^CD138^hi^ and total CD138^hi^ cells were present in comparable numbers in the two groups of mice ([Figures 7](#fig7){ref-type="fig"}D, 7E, and [S7](#mmc1){ref-type="supplementary-material"}E). Consistently, CD72 deficiency led to higher bacterial load and reduced survival ([Figure 7](#fig7){ref-type="fig"}F), compromising vaccine efficacy. Memory T helper 1 (Th1) cells play a major role in vaccine-induced protection against *Salmonella*. In vaccinated *Cd72*^*−/−*^ mice, numbers of memory *Salmonella*-reactive Th1 CD4^+^ T cells in the BM were reduced ([Figures 7](#fig7){ref-type="fig"}G and [S7](#mmc1){ref-type="supplementary-material"}F), and accumulation of exhausted PD-1^+^CD4^+^ T cells, PD-1^+^CD8^+^ T cells, and regulatory Foxp3^+^CD4^+^ T cells were increased ([Figures 7](#fig7){ref-type="fig"}H and [S7](#mmc1){ref-type="supplementary-material"}G).

These data demonstrate that in the absence of CD72, a higher accumulation of LAG-3^+^CD138^hi^ plasma cells is associated with impaired immunity to *Salmonella*.

Discussion {#sec3}
==========

This study demonstrates the existence of natural regulatory plasma cells, which are the major source of IL-10 early after infection with *Salmonella*.

An unexpected finding was that the cells expressing IL-10 were not reactive plasmablasts but instead resident plasma cells. Upon activation, B cells successively generated antibody-secreting plasmablasts that proliferated and then plasma cells that did not divide and expressed higher amounts of the transcription factor BLIMP-1. LAG-3^+^CD138^hi^ cells were non-proliferating and expressed higher amounts of BLIMP-1 than LAG-3^−^CD138^hi^ cells, thus qualifying as *bone fide* plasma cells. Their non-dividing status correlated with the lack of expression of factors necessary for cell division including the transferrin receptor CD71 and the transcriptional regulator Foxm1, as well as the increased expression of the cell proliferation inhibitors *Egr2*, *Zfp36l1*, *Pdcd4*, *Klf4*, and *Bhlhe40*. KLF4 is absent in plasmablasts generated *in vitro* but is expressed in long-lived BM plasma cells ([@bib26]). LAG-3^+^CD138^hi^ cells thus display a profile of mature plasma cells, while retaining the capacity to respond to external stimuli, in particular TLR, via the production of IL-10.

LAG-3^+^CD138^hi^ plasma cells expressed several immune checkpoint receptors implicated in the negative regulation of immunity such as LAG-3, PD-L1, PD-L2, and CD200. LAG-3 is a co-inhibitory receptor related to CD4 and implicated in the down-modulation of T cell immunity. The co-expression of several inhibitory molecules is important because these molecules usually act synergistically, so that their combined blockade achieves greater effect than the neutralization of single molecules. Blockade of LAG-3 and PD-L1 augments immunity toward *Plasmodium falciparum* by amplifying T cell activation and antibody production ([@bib4]). Here, we found that LAG-3 on plasma cells did not influence their IL-10 expression, but inhibited the accumulation of IL-10^−^CD138^hi^ cells, which were LAG-3^−^, early after infection. The suppressive function of LAG-3^+^CD138^hi^ cells therefore extends beyond IL-10 production, suggesting a more global role in immune regulation.

LAG-3^+^CD138^hi^ cells developed from several B cell subsets in a BCR-dependent manner. Their preserved accumulation in germ-free mice suggests that they are selected on self-antigens. Our study has not identified the antigens involved in the generation of LAG-3^+^CD138^hi^ cells. Since these cells increased with age, which has also been associated with an accumulation of damaged cells ([@bib2]), it is tempting to speculate that LAG-3^+^CD138^hi^ cells react toward antigens released by damaged cells. This hypothesis is consistent with the recognition by natural IgM of senescent cells ([@bib12]) and by natural antibodies binding PtC of apoptotic cells ([@bib28]). LAG-3^+^CD138^hi^ cells may thus provide a feedback mechanism, which senses the number of damaged cells and proportionally downregulates the activation of immunity to limit additional and potentially excessive immunopathology when an immune stimulus arises. Mice lacking the BCR inhibitory co-receptor CD72 had an increased abundance of LAG-3^+^CD138^hi^ cells and an impaired capacity to control *Salmonella* infection. The induction of IL-10 in LAG-3^+^CD138^hi^ cells was primarily controlled by TLR. We cannot, however, exclude that BCR signaling played a role in IL-10 production, even if it was not the major switch for IL-10 expression. For instance, it might contribute to the transcription of *Il10* in LAG-3^+^CD138^hi^ cells at steady state in naive mice and synergize with TLR to upregulate IL-10 expression after challenge. It is indeed possible that these cells express BCR that recognize endogenous antigens already available at steady state and persisting during challenge.

In conclusion, natural regulatory plasma cells can rapidly provide a first layer of B cell-mediated immune regulation in response to TLR signals. They might subsequently be complemented by other subsets of suppressive B cells and plasma cells induced in an antigen-specific manner.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**B220BioLegendClone RA3-6B2; RRID: [AB_2563491](nif-antibody:AB_2563491){#intref0010}CD1dBD PharMingen/BioLegendClone 1B1; RRID: [AB_2073521](nif-antibody:AB_2073521){#intref0015}, [AB_1236543](nif-antibody:AB_1236543){#intref0020}CD3BioLegendClone 145-2C11; RRID: [AB_893317](nif-antibody:AB_893317){#intref0025}CD4BioLegendClone GK1.5 or RM4-5; RRID: [AB_893323](nif-antibody:AB_893323){#intref0030}, [AB_10898318](nif-antibody:AB_10898318){#intref0035}CD5BD PharMingen/BioLegendClone 53-7.3; RRID: [AB_394559](nif-antibody:AB_394559){#intref0040}, [AB_2563930](nif-antibody:AB_2563930){#intref0045}CD8BioLegendClone 53-6.7; RRID: [AB_893423](nif-antibody:AB_893423){#intref0050}, [AB_2561389](nif-antibody:AB_2561389){#intref0055}CD11bBioLegendClone M1/70; RRID: [AB_755986](nif-antibody:AB_755986){#intref0060}, [AB_830642](nif-antibody:AB_830642){#intref0065}CD11cBioLegendClone N418; RRID: [AB_830649](nif-antibody:AB_830649){#intref0070}, [AB_389306](nif-antibody:AB_389306){#intref0075}CD19BioLegendClone 6D5; RRID: [AB_493734](nif-antibody:AB_493734){#intref0080}, [AB_830707](nif-antibody:AB_830707){#intref0085}CD21/35BD PharMingen/BioLegendClone 7G6/7E9; RRID: [AB_395070](nif-antibody:AB_395070){#intref0090}, [AB_1953277](nif-antibody:AB_1953277){#intref0095}CD23BD PharMingen/BioLegendClone B3B4; RRID: [AB_394652](nif-antibody:AB_394652){#intref0100}, [AB_2103038](nif-antibody:AB_2103038){#intref0105}, [AB_312829](nif-antibody:AB_312829){#intref0110}CD24BioLegendClone M1/69; RRID: [AB_2563464](nif-antibody:AB_2563464){#intref0115}CD40LMiltenyi BiotecClone MR1; RRID: [AB_2661127](nif-antibody:AB_2661127){#intref0120}CD40DRFZClone FGK-45CD43BD PharMingenClone S7; RRID: [AB_10895376](nif-antibody:AB_10895376){#intref0125}CD69DRFZClone H1.2F3CD71BioLegendClone RI7217; RRID: [AB_313564](nif-antibody:AB_313564){#intref0130}CD72BD PharMingenClone K10.6; RRID: [AB_393982](nif-antibody:AB_393982){#intref0135}CD79αBioLegendClone F11-172; RRID: [AB_2075634](nif-antibody:AB_2075634){#intref0140}CD79βBioLegendClone HM79-12; RRID: [AB_1575061](nif-antibody:AB_1575061){#intref0145}CD81BioLegendClone Eat-2; RRID: [AB_313138](nif-antibody:AB_313138){#intref0150}CD93eBioscienceClone AA4.1; RRID: [AB_469466](nif-antibody:AB_469466){#intref0155}CD138BD PharMingen/BioLegendClone 281-2; RRID: [AB_395000](nif-antibody:AB_395000){#intref0160}, [AB_2565621](nif-antibody:AB_2565621){#intref0165}CD200BioLegendClone OX-90; RRID: [AB_10900996](nif-antibody:AB_10900996){#intref0170}CXCR3BioLegendClone CXCR3-173; RRID: [AB_1088994](nif-antibody:AB_1088994){#intref0175}Foxp3eBioscienceClone FJK-16 s; RRID: [AB_465243](nif-antibody:AB_465243){#intref0180}, [AB_465936](nif-antibody:AB_465936){#intref0185}Fc receptorDRFZClone 2.4G2FASBD PharMingenClone Jo2; RRID: [AB_396768](nif-antibody:AB_396768){#intref0190}GL-7BD PharMingenClone GL7; RRID: [AB_10894953](nif-antibody:AB_10894953){#intref0195}IgMBioLegendClone RMM-1; RRID: [AB_2650758](nif-antibody:AB_2650758){#intref0200}IgDBioLegendClone 11-26c.2a; RRID: [AB_2562887](nif-antibody:AB_2562887){#intref0205}IFN-γBD PharMingen/BioLegendClone XMG1.2; RRID: [AB_2034014](nif-antibody:AB_2034014){#intref0210}, [AB_1595591](nif-antibody:AB_1595591){#intref0215}Ki-67BioLegendClone 16A8; RRID: [AB_2561929](nif-antibody:AB_2561929){#intref0220}LAG-3 (CD223)eBioscienceClone C9B7W; RRID: [AB_494214](nif-antibody:AB_494214){#intref0225}, [AB_2573428](nif-antibody:AB_2573428){#intref0230}MHC-IIDRFZClone M5/114PD-1BioLegendClone 29F.1A12; RRID: [AB_2251944](nif-antibody:AB_2251944){#intref0235}TCR-βBD PharMingenClone H57-597; RRID: [AB_10584335](nif-antibody:AB_10584335){#intref0240}TNF-αBD PharMingen/BioLegendClone MP6-XT22; RRID: [AB_2562918](nif-antibody:AB_2562918){#intref0245}, [AB_469508](nif-antibody:AB_469508){#intref0250}PD-L1BD PharMingenClone MIH5; RRID: [AB_397018](nif-antibody:AB_397018){#intref0255}PD-L2BioLegendClone TY25; RRID: [AB_2566345](nif-antibody:AB_2566345){#intref0260}VH11Prof. Kyoko Hayakawa (Fox Chase Cancer Center, Philadelphia, USA)Clone P18-3H7Vk14 (Vk9)Prof. Kyoko Hayakawa (Fox Chase Cancer Center, Philadelphia, USA)Clone P18-13B5VH12Prof. Klaus Rajewsky (MDC Berlin)Clone 5C5IL-10BioXCellClone JES5-2A5; RRID: [AB_1107696](nif-antibody:AB_1107696){#intref0265}IL-10RBioXCellClone 1B1.3A; RRID: [AB_1107611](nif-antibody:AB_1107611){#intref0270}Ig (H+L)Southern BiotechnologyCat. \#1010-01; RRID: [AB_609680](nif-antibody:AB_609680){#intref0275}IgM-APSouthern BiotechnologyCat. \#1020-04; RRID: [AB_619829](nif-antibody:AB_619829){#intref0280}IgG-APSouthern BiotechnologyCat. \#1030-04; RRID: [AB_609689](nif-antibody:AB_609689){#intref0285}IgG1-APSouthern BiotechnologyCat. \#1070-04IgG2b-APSouthern BiotechnologyCat. \#1090-04; RRID: [AB_619828](nif-antibody:AB_619828){#intref0290}IgG2c-APSouthern BiotechnologyCat. \#1079-04; RRID: [AB_2692321](nif-antibody:AB_2692321){#intref0295}IgG3-APSouthern BiotechnologyCat. \#1100-04IgA-APSouthern BiotechnologyCat. \#1040-04; RRID: [AB_619826](nif-antibody:AB_619826){#intref0300}Goat Anti-Human IgG-UNLBSouthern BiotechCat. \#2040-01; RRID: [AB_617099](nif-antibody:AB_617099){#intref0305}Goat Anti-Human IgG-BiotinSouthern BiotechCat. \#2040-08Human IgG standardSigma-AldrichCat. \#I2511; RRID: [AB_1163604](nif-antibody:AB_1163604){#intref0310}Streptavidin-Alexa 488Thermo Fisher ScientificCat. \#S32354Streptavidin-PEBD PharMingenCat. \#554061Streptavidin-APCBD PharMingenCat. \#554067Streptavidin-APC-Cy7BioLegendCat. \#405208Streptavidin-BV421BioLegendCat. \#405225Streptavidin-BV605BioLegendCat. \#405229Streptavidin-BV785BioLegendCat. \#405249Streptavidin-PE/Cy7BD PharMingenCat. \#557598Streptavidin-PerCPBD PharMingenCat. \#554064Anti-PEMiltenyi BiotecCat. \#130-048-801; RRID: [AB_244373](nif-antibody:AB_244373){#intref0315}B-1a Cell Isolation KitMiltenyi BiotecCat. \#130-097-413CD19Miltenyi BiotecCat. \#130-052-201CD43Miltenyi BiotecCat. \#130-049-801CD11bMiltenyi BiotecCat. \#130-049-601CD11cMiltenyi BiotecCat. \#130-052-001CD4Miltenyi BiotecCat. \#130-049-201CD8Miltenyi BiotecCat. \#130-049-401CD90.2Miltenyi BiotecCat. \#130-049-101**Chemical Peptides and Recombinant Proteins**DAPISigmaCat. \#D8417Propidium IodideSigmaCat. \#P4864GlutaraldehydeElectron Microscopy SciencesCat. \#16220OsmiumtetroxidePolysciencesCat. \#0223DTannic acidPolysciencesCat. \#04459Uranyl acetateTed Pella incCat. \#19481CutSmart BufferNEBCat. \#B7204STrypsin 0.5% EDTALife TechnologiesCat. \#253000542-MercaptoethanolLife TechnologiesCat. \#31350010Calcium chlorure dihydratedRothCat. \#5239.2TMBEbioscienceCat. \#00-4201-56Tween20Sigma-AldrichCat. \#P1379**Critical Commercial Assays**Gene Chip Mouse 430 2.0Affymetrix GmbHCat. \#900495Mouse Cell Screening (PE) kitBioLegendCat. \#700003Foxp3 Staining Buffer SetEbioscienceCat. \#00-5523-00BD Cytofix/Cytoperm Plus KitBD PharMingenCat. \#554715One Step RT-PCR kitQIAGENCat. \#210212Reverse Transcription SystemPromegaCat. \#A3500LightCycler FastStart DNA MasterPLUS SYBR GreenRoche DiagnostikCat. \#03515885001Bio-Plex Pro Mouse Cytokine IL-10 Set, 1 × 96 wellBio-RadCat. \#171-G5009M**Deposited Data**Gene array dataThis paperGEO: [GSE103458](ncbi-geo:GSE103458){#intref0320}RNA-seq and DNA methylation dataThis paperENA: PRJEB22138**Other**Expression vectors containing the human IGG1 constant regionsProf. Dr. Hedda Wardemann, (DKFZ, Heidelberg)N/AExpression vectors containing the human IGK constant regionsProf. Dr. Hedda Wardemann, (DKFZ, Heidelberg)N/AExpression vectors codings for Human monoclonal antibody\
mGO53Prof. Dr. Hedda Wardemann, (DKFZ, Heidelberg)N/AExpression vectors codings for Human monoclonal antibody\
JB40Prof. Dr. Hedda Wardemann, (DKFZ, Heidelberg)N/AExpression vectors codings for Human monoclonal antibody\
ED38Prof. Dr. Hedda Wardemann, (DKFZ, Heidelberg)N/APtC-containing Liposomes labeled with Texas RedFormuMaxCat. \#F60103F-TRLipopolysaccharides from *Escherichia coli* 055:B5SigmaCat. \#L2637-25MGTamoxifenSigmaCat. \#T5648-1GSunflower seed oil from Helianthus annuusSigmaCat. \#S5007-250MLNP-KLHBioCat GmbHCat. \# N-5060-25NP-LPSBioCat GmbHCat. \# N-5065NP-AECM-FICOLLBioCat GmbHCat. \# F-1420AffiniPure Fab2 Fragment Goat Anti-Mouse IgMDianova GmbHCat. \#115-006-075MacConkey AgarBecton Dickinson GmbHCat. \#212123RNeasy Mini KitQIAGENCat. \#74106Recombinant murine IL-6 proteinR&D Systems GmbHCat. \#406-ML-005Recombinant murine IL-21 proteinR&D Systems GmbHCat. \#594-ML-010MultiScreenHTS IP Filter PlateMilliporeCat. \#MSIPN4510BCIP/NBT substrateThermo Fisher ScientificCat. \#34042Proteinase KSigma AldrichCat. \#P2308Pefabloc SCSigma AldrichCat. \#76307HaeIIINew England BiolabsCat. \#R0108MKlenow Fragment exo-New England BiolabsCat. \#M0212LT4-LigaseNew England BiolabsCat. \#M0202MT4-LigaseNew England BiolabsCat. \#M0202LRNase HNew England BiolabsCat. \#M0297LDNA Polymerase INew England BiolabsCat. \#M0209LNEBNext High-Fidelity 2X PCR Master MixNew England BiolabsCat. \#M0541LTruSeq DNA PCR-Free LT Library Preparation Kit - Set AIlluminaCat. \#FC-121-3001Nextera DNA Sample Preparation KitIlluminaCat. \#FC-121-1030EZ DNA Methylation-Gold KitZymo researchCat. \#D5006HotStarTaq DNA PolymeraseQIAGENCat. \#203207MinElute PCR Purification KitQIAGENCat. \#28006Agencourt AMPure XPBeckman CoulterCat. \#A63881mRNA Capture KitRocheCat. \#11787896001M-MLV Reverse Transcriptase, RNase H Minus, Point MutantPromegaCat. \#M3683Agilent High Sensitivity DNA KitAgilentCat. \#5067-4626Pfu polymerasePromegaCat. \#M7745Hot Taq polymerasePromegaCat. \#M7805dNTP Master MixEurogentecCat. \#NU-0010-100AgeI--HFNEBCat. \#R3552LSalI--HFNEBCat. \#R3138LBsiWINEBCat. \#R0553LNEBuffer 1NEBCat. \#B7001SGel and PCR clean up kitMacherey-NagelCat. \#740609.25010X Buffer T4 ligasePromegaCat. \#C126AT4 ligasePromegaCat. \#M180BOne Shot TOP10 Chemically Competent E.coliInvitrogenCat. \#C404006Luria BrothDutscherCat. \#777495Luria AgarDutscherCat. \#777494S.O.C MediumLife TechnologiesCat. \#15544034Ampicillin sodium saltSigma-AldrichCat. \#A9518NucleoSpin PlasmidMacherey-NagelCat. \#740588.250NucleoSpin 96 Plasmid Transfection-gradeMacherey-NagelCat. \#740491.4DMEMLife TechnologiesCat. \#61965026FBS South AmericaBIOWESTCat. \#S1810-500Penicillin/Streptomycin solLife TechnologiesCat. \#15140-122Nutridoma-SPSigma-AldrichCat. \#11011375001Double strand DNASigma-AldrichCat. \#31149-10G-FInsulinSigma-AldrichCat. \#I9278-5MLBovine Serum AlbuminSigma-AldrichCat. \#A7906-100GExtravidin, Peroxidase ConjugateSigma-AldrichCat. \#E2886-1ML

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Simon Fillatreau (<simonfillatreau@googlemail.com>). Certain materials are shared with academic and non-profit research organizations for research and educational purposes only under an MTA to be discussed in good faith with the recipient.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

C57BL/6, *Il10*eGFP ([@bib22]), *Btk*^−/−^, *Cd72*^−/−^, *Cd19*^−/−^, *Cd1d*^−/−^, *Nos2*^−/−^, *Rag2*^−/−^, B1-8i*Igk*^−/−^, *Fcγr2b*^−/−^, *Cd19*-cre-*Notch2*^*fl/fl*^, *Il10*^−/−^, *Lag3*^−/−^ ([@bib21], [@bib35]), *Tcrα/β*^−/−^, *Cd40*^−/−^, *Myd88*^−/−^, *Myd88*^−/−^*Trif*^−/−^, J~H~T, *Cd72*^−/−^J~H~T, *Prdm1*eGFP, *Cd72*^−/−^*Il10*eGFP, *Lag3*^−/−^*Il10*eGFP, *Cd21*-cre-ROSA-STOP-eYFP, *Aicda*-cre-ERT2-ROSA-STOP-RFP, C3H/HeOuJ were bred under specific pathogen-free conditions. C3H/HeOuJ mice were also bred under germ-free conditions. Mouse strains used in infection experiments were NrampS. B-*Lag3*^−/−^ mice were obtained by reconstituting recipient mice with a mixture of bone marrow cells from B cell-deficient J~H~T mice (80%) and *Lag3*^−/−^ mice (20%). Control B-WT chimera was obtained using a mixture of bone marrow cells from J~H~T mice (80%) and C57BL/6 mice (20%). B-*Lag3*^−/−^*Il10*eGFP and their B-*Il10*eGFP controls were obtained using the same strategy. All experiments were reviewed and approved by appropriate institutional review committees (LAGeSo Berlin), and were conducted according to French, and German legislations, in compliance with European community council directive 68/609/EEC guidelines. Mice were of C57BL/6 strain, 6-14 weeks old at start of experiments, unless otherwise stated, and of sex-matched male and female genders.

Method Details {#sec4.4}
--------------

### Bacterial infection {#sec4.4.1}

Mice were infected with 1x10^6^ or 1x10^7^ CFU for *Salmonella typhimurium* SL7207 strain or 100 CFU for SL1344 strain intravenously (i.v.). For survival and vaccination plus rechallenge experiments mice were first vaccinated with 1x10^6^ CFU of SL7207 given i.v. and 90 days later were rechallenged with 100 CFU of SL1344 or 1x10^6^ or 10^7^ CFU of SL7207. During survival experiments, mice were daily checked and presented as percentage of live animals. The bacterial loads were determined by plating a series of dilutions of homogenized organs on MacConkey agar plates. Heat-killed *S. typhimurium* (HKST) was prepared by inactivation of the SL1344 strain in water bath at 70°C for 1 hour. Bacteria were suspended in PBS. *Salmonella* infection was performed in a blinded manner, and identities of the mice were revealed upon termination of the experiment. No randomization was used. Estimation of size groups was based on our previous experience with these disease models, without *a priori* determination via power calculation. For neutralization of IL-10 signaling, mice were treated i.v. with a combination of anti-IL-10 (JES5-2A5; 500 μg/mouse/injection; BioXCell) and anti-IL-10R (1B1.3A; 500 μg/mouse/injection; BioXCell) on days −3, −1, and +1 after infection.

### Tamoxifen administration {#sec4.4.2}

Tamoxifen was resuspended in sunflower seed oil from Helianthus annuus to a final concentration of 20mg/ml. 10mg of tamoxifen was administered by gavage to *Aicda*-cre-ERT2-ROSA-STOP-RFP mice twice with 5 days interval between the first and second administration. Mice were analyzed 15 days after the last administration.

### Immunization and treatment with agonists of BCR, CD40, TLR4 {#sec4.4.3}

C57BL/6 mice were immunized i.p. with 200 μg NP-KLH precipitated in alum, NP-Ficoll, or NP-LPS. Mice were analyzed 7 days after immunization. In house conjugated APC or PE nitrophenyl hapten was used to detected NP specific B and plasmocytes.

*Il10*eGFP mice were injected i.v. with 100 μg anti-BCR (Fab2 anti-mouse IgM), 50 μg anti-CD40 (FGK-45), or 10 μg LPS (*E. coli* 055:B5), alone or in combination. Mice were analyzed 24h later.

### Isolation of plasmocytes and B cells {#sec4.4.4}

For gene array, quantitative PCR, restimulation *in vitro*, ELISPOT assays and transmission electron microscopy analysis, plasmocytes and B cell subsets were obtained from C57BL/6 or *Il10*eGFP mice, naive or on day 1 p.i. with 10^7^ CFU *Salmonella* (SL7207) by a two steps process. First, CD138^+^ cells were enriched by autoMACS after incubation with anti-CD138-PE followed by anti-PE microbeads. CD138^+^ cells obtained after autoMACS were then stained with anti-CD19, CD138, LAG-3, CD22 and CD11b/CD11c/TCR-β/DAPI. The following populations were sorted by FACS Sorter Aria I and/or II from this fraction: CD138^hi^CD22^+^LAG-3^-^CD11b^-^CD11c^-^TCR^-^β^-^DAPI^-^, CD138^hi^CD22^-^LAG-3^-^CD11b^-^CD11c^-^TCR^-^β^-^DAPI^-^, CD138^hi^CD22^-^LAG-3^+^CD11b^-^CD11c^-^TCR^-^β^-^DAPI^-^, CD138^hi^CD11b^-^CD11c^-^TCR^-^β^-^DAPI^-^, CD138^hi^*Il10e*GFP^+^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^ and CD138^hi^*Il10*eGFP^-^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^, CD138^hi^LAG-3^+^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^ and CD138^hi^LAG-3^-^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^. The cells from the CD138-negative fraction after autoMACS were stained with anti-CD19, CD138, CD1d, CD21, CD23 and CD11b/CD11c/TCR-β/DAPI. CD19^+^CD138^-^CD11b^-^CD11c^-^TCRβ^-^DAPI^-^; CD19^+^CD1d^hi^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^ and CD19^+^CD1d^low^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^; CD19^+^CD1d^low^CD21^+^CD23^+^CD11b^-^CD11c^-^TCR^-^β^-^DAPI^-^ (FO) and CD19^+^CD1d^high^CD21^high^CD23^low/-^CD11b^-^CD11c^-^TCR^-^β^-^DAPI^-^ (MZ) were then isolated from this fraction by FACS Sorter Aria I and/or II. Total B cells were obtained by magnetic isolation using negative selection with anti-CD11b, CD11c, and CD43 microbeads. For PeC, cells were incubated with B-1a Cell Biotin-Antibody Cocktail (Miltenyli Biotec) for 5 minutes at 2-8°C and then with anti-Biotin Microbeads for an additional 10 minutes in the same conditions in order to deplete non-B cells, according to Manufacturer's instructions. LD columns were used for removing the non-B cells. Unlabeled cells were collected representing the pre-enriched B1a cell fraction that contained all PeC B cells fractions.

For single cell sorting, single CD138^hi^*Il10*eGFP^+^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^ or CD138^hi^*Il10*eGFP^-^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^, CD138^hi^LAG-3^+^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^, CD138^hi^LAG-3^-^CD11b^-^CD11c^-^TCR-β^-^DAPI^-^ plasmocytes were directly sorted into 96-well PCR plates supplemented 1X RT-PCR buffer. Plates were then covered with microseal B film and immediately frozen on dry ice before storage at −80°C for further experiments.

For epigenetic and RNaseq analysis plasmocyte and B cell populations were sorted by FACS Sorter Aria I and/or II from spleen and PeC of naive C57BL/6 mice using the gating strategy illustrated in Methods S1.

For adoptive transfer, 10^6^ of flow cytometry-sorted B1a, B1b, and B2 cells from PeC, as well as CD19^+^CD138^-^ splenic B cells were administered i.p. into *Rag2*^−/−^ mice, which were analyzed 3 weeks later.

### B cell stimulation and cytokine production measurement {#sec4.4.5}

Plasmocytes and/or B cell subsets were stimulated at 5x10^5^ or 1x10^5^ cells per well in 96-well flat or round bottom plates, respectively, in complete RPMI or with LPS (1μg/ml), α-IgM (Fab) (Dianova GmbH, 5μg/ml), agonistic α-CD40 antibody (clone FGK-45, produced in house at 10μg/ml), and in combinations in the presence of IL-6 (20ng/ml; R&D Systems GmbH), IL-21 (20ng/ml; R&D Systems GmbH). For analysis of cytokine production, 150μl supernatant of activated cells was collected and transferred into new 96 well plates and kept at −20°C until further use. 50μl of supernatant was used to measure cytokine concentration using Bio-Plex kits (Bio-Rad) according to the manufacturer's instruction.

### Transmission Electron Microscopy {#sec4.4.6}

Sorted cells, fixed in 2.5% glutaraldehyde (EM grade), were sedimented in warm low melting agarose (2% in PBS) and left to set. Excised bits of agarose containing cell-groups were then postfixed in 0.5% osmium tetroxide, contrasted with tannic acid and 2% uranyl acetate, dehydrated in a graded ethanol series and embedded in epoxy resin. After polymerization, sections were cut at 60 nm and contrasted with lead citrate. Specimens were analyzed in a Leo 906E transmission electron microscope at 100KV (Zeiss, Oberkochen, DE) using a side mounted digital camera (Morada; SIS-Olympus Münster DE).

### Gene array hybridization {#sec4.4.7}

cRNA were hybridized on Affymetrix MG 430 2.0 arrays using standard Affymetrix protocol after quality control with Agilent 2100 Bioanalyzer and quantification with NanoDrop ND-1000 spectrophotometer.

### Library preparation for methylation analysis of plasmocytes and B cell subsets {#sec4.4.8}

Sorted cells were lysed and digested with proteinase K followed by addition of 1mM Pefabloc SC (Sigma-Aldrich) to inhibit protease activity. Cell lysates were digested overnight with 50U HaeIII (New England Biolabs) followed by inactivation at 80°C. A-tailing was performed using 5U Klenow exo^-^ (New England Biolabs), and Illumina TruSeq adaptors were ligated at 16°C overnight using 2000U T4-Ligase (New England Biolabs). DNA fragments were purified with 1.5x Agencourt AMPure XP (Beckman Coulter) and bisulfite treated using the EZ DNA Methylation-Gold Kit (Zymo research) following the manufacturer's protocol. The libraries were amplified by 14-15 cycles of PCR using HotStarTaq DNA Polymerase (QIAGEN), and purified with 0.9x Agencourt AMPure XP (Beckman Coulter). The library quality was assessed using Agilent 2100 Bioanalyzer, and the quantity was measured using Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific). The Illumina HiSeq 2500 system was used for 100 bp single-end sequencing.

### Library preparation for mRNA Seq {#sec4.4.9}

mRNA Capture Kit (Roche) was used to isolate mRNA with the modification that cell pellets (10^5^ cells) were lysed in 49μl lysis buffer, and 1μl of the biotin labeled oligo(dT)~20~ working solution was added to the lysate. After immobilization and washing of mRNA in streptavidin coated tubes first strand synthesis was performed in 50μl using 400U M-MLV Reverse Transcriptase RNase H^-^ (Promega) at 37°C for 1h. For second strand synthesis 400U T4-Ligase, 5U RNase H, and 50U DNA Polymerase I (New England Biolabs) were used at 16°C for 2.5h. The double stranded cDNA was fragmented and tagged with sequencing adapters using the Nextera DNA Library Preparation Kit (Illumina) with the deviation that 0.2μl of the Tagment DNA Enzyme 1 were used in a 50μl reaction. After incubation at 55°C for 5 minutes the reaction was stopped and the DNA was released from the tubes by the addition of 250μl of Buffer PB (QIAGEN). The DNA was purified using MinElute PCR Purification Kit (QIAGEN) following the manufacturer's protocol, and the elution step was performed with 11.5μl distilled water. The libraries were amplified for 12 cycles using NEBNext High-Fidelity 2X PCR Master Mix (New England Biolabs) and 0.2μM Index adapters (AATGATACGGCGACCACCGAGATCTACAC\[i5\]TCGTCGGCAGCGTC and CAAGCAGAAGACGGCATACGAGAT\[i7\]GTCTCGTGGGCTCGG). The libraries were purified with 0.8x Agencourt AMPure XP (Beckman Coulter), and sequenced using the Illumina HiSeq 2500 system with 1x100 bp single-end reads.

### Analysis of mRNA expression by B cells and plasmocytes {#sec4.4.10}

Sorted or cultured B cells and plasmocytes were lysed in RLT buffer (QIAGEN) and kept at −80°C until use. Total RNA was extracted using RNeasy Mini Kit (QIAGEN) according to the manufacturer's instruction. After DNase treatment, cDNA was synthesized from RNA with a Reverse Transcription System (Promega). Quantitative RT-PCR was performed on an MX3005P QPCR System (Stratagene), with LightCycler FastStart DNA Master SYBR Green I (Roche). Transcripts were quantified using β-actin as standard, and the following forward (FP) and reverse (RP) primers (MWG Biotech): β-actin FP: 5′-TGGAATCCTGTGGCATCCATGAAAC-3′, β-actin RP: 5′-TAAAACGCAGCTCAGTAACAGTCC-3′; IL-10 FP: 5′-AGCCGGGAAGACAATAAC TG-3′, IL-10 RP: 5′-CATTTCCGATAAGGCTTG G-3′.

### Ig gene amplification from single cells {#sec4.4.11}

Single cells sorted in 96-well PCR plate were immediately frozen on dry ice and stored at −80°C until further use. To amplify Ig gene from single cells, a nested PCR approach was used. Reverse transcription (RT) and the first PCR step for *Igμ* (IgM) and *Igκ* variable gene transcripts were carried out in a one-step reaction using the QIAGEN OneStep RT-PCR kit according to the manufacturer's instructions. The Ig gene primers were chosen based on [@bib33]. The second round of PCR was carried out with 2μl of a 100-fold dilution of the unpurified first PCR product at 94°C for 4 minutes followed by 50 cycles of 94°C for 30 s, 60°C (*Igμ*) or 48°C (*Igκ*) for 30 s, 72°C for 45 s, and final incubation at 72°C for 10 minutes. The second PCR products were analyzed on 2% agarose gels.

The Ig gene PCR products from different plasmocyte subsets were sequenced (LGC) with the respective forward primers. Nucleotide sequences were then analyzed using IMGT/V-Quest to determine germline V, D, and J gene members, somatic hypermutation (counted for CDR1-FWR3 inclusively), CDR3 sequences, N-nucleotide addition.

### Cloning of mouse Ig genes into expression vectors {#sec4.4.12}

After identifying V and J gene segment, second PCR reactions were repeated using 5μl of a 100-fold dilution of the unpurified first PCR product as template with specific V and J gene primers containing restriction sites to clone directly into expression vectors. PCR products were purified using Gel and PCR clean up kit before digestion with AgeI and SalI (Igh), AgeI and BsiWI (Igk). Digested Igh and Igk PCR products were purified from 0.9% agarose before ligation into expression vectors containing the human IGG1 and IGK constant regions, respectively. Ligation products were transformed into competent *E.Coli* via heat shock at 42°C, then *E.Coli* cells were plated on Ampicillin plates (100μg/ml) overnight at 37°C. Inserted genes were screened by PCR in Ampicillin resistant bacterial colonies.

### Expression of recombinant immunoglobulin {#sec4.4.13}

Four single positively bacterial clones of each Igh and Igk gene were grown overnight at 37°C in 5ml of LB medium containing 100μg/ml Ampicillin. Plasmids were purified using NucleoSpin Plasmid - plasmid Miniprep kit (Macherey-Nagel), followed with digestion and analysis on 1% agarose. Inserted plasmids were then sequenced (GATC) to confirm identity with the second round PCR product and no mutation which probably is introduced by polymerase.

One day before transfection, 4x10^6^ HEK293 T cells were plated in T175 culture flasks in complete DMEM (DMEM + 10% (v/v) FCS + Penicillin (100U/ml)/Streptomycin (100 μg/ml) + 2-Mercaptoethanol (50 μM). The cell should be 80% confluency on the day of transfection. Transient transfections were performed with calcium-phosphate precipitation. In brief, equal amounts of IgH (7μg) and corresponding IgK chain vector were mixed with sterile water and 124μl of 2M CaCl~2~. An equal volume of 1ml of 2X HBS was added drop-wise to the above mixture under slow vortexing and incubated at room temperature for 15min to allow formation of precipitates. The resulting solution was distributed to the culture flask. On the next day, cells were washed with 5ml of serum-free DMEM and 20ml of DMEM supplemented with 1% Nutridoma-SP, Penicillin (100U/ml)/Streptomycin (100 μg/ml) and 2-Mercaptoethanol (50 μM) was added. Supernatant were harvested at day 6 post transfection, cell debris was removed by centrifugation at 800 g for 10 minutes and culture supernatants were stored at −20°C.

### Detection of antibody reactivity by ELISAs {#sec4.4.14}

IgG concentration in the supernatants were determined by ELISA. In brief, enhanced protein-binding ELISA plates were coated with 50μl of Goat Anti-Human IgG-UNLB diluted in carbonate buffer as capture antibody at 4°C overnight. Plates were washed 3 times with PBS. Unspecific binding was blocked by 200μl PBS/ 3%BSA for 1 hour at 37°C and washed again 4 times with PBS/0.1% Tween. Human IgG standard and culture supernatants were added, incubated for 2 hours at 37°C and washed again to remove unbound antibody with PBS/0.1% Tween. 100μl of Biotinylated Goat Anti-Human IgG Secondary Antibody was added, incubated for 1 hour at room temperature and washed again with PBS/0.1% Tween prior to adding ExtrAvidin^®^−Peroxidase for 1 hour at room temperature. After washing, assays were developed using 100μl TMB solution and incubated at RT for color development. Assays were stopped by H~2~SO~4~ and ODs were measured at 450nm. Antibody concentration was determined by Softmax Pro software.

Antibodies with concentration higher than 5μg/ml were selected to test for polyreactivity with LPS, dsDNA and Insulin by ELISA. In brief, enhanced protein-binding ELISA plates were coated with 50μl of LPS (10μg/ml) or insulin (10μg/ml) or dsDNA (10μg/ml) in carbonate buffer and incubated at 4°C overnight. After washing, plates were incubated with 100μl nonpurified antibodies for 2 hours at 37°C and washed again. Nonpolyreactive (mGO53), low polyreactive (JB40), highly polyreactive (ED38) recombinant human monoclonal antibodies served as controls and were included on each plate. Unbound antibodies were removed by washing 4 times with PBS/0.1% Tween before detected using Biotinylated Goat Anti-Human IgG Secondary Antibody, followed with ExtrAvidin^®^−Peroxidase for 1 hour at room temperature. The rest steps were performed as above mentioned.

### Cell staining for flow cytometry {#sec4.4.15}

For surface staining, splenocytes, BM, PeC, and lymph node cells were first incubated with anti-Fc receptor antibody (clone 2.4G2) for 15 minutes to block unspecific bindings, and surface staining was then performed with antibodies conjugated directly with fluorochrome for 15 minutes. For biotinylated antibodies, cells were further incubated with Streptavidin conjugated to fluorochrome for 15 minutes. Dead cells were excluded by DAPI or PI.

For cytokine intracellular staining, cells were plated at 5x10^6^ cells per well in flat-bottom 48-well plates with 1ml complete RPMI 1640 containing HKST for 1 hour. Golgistop was added afterward, and cells were incubated for 5 more hours. Cells were harvested and stained for surface markers, including uncoupled pacific orange to exclude dead cells before cells were fixed. Intracellular staining was performed with Cytofix/Cytoperm kit (BD) as recommended.

Ki67 (BioLegend) and Foxp3 nuclear stainings were performed with Foxp3 staining kit (Ebioscience). Stained cells were acquired on FACS Symphony, Fortessa, Canto, LSR II and analyzed with FlowJo software.

### ELISPOT Assay {#sec4.4.16}

Sorted day 0 CD138^hi^LAG-3^+^ and CD138^hi^LAG-3^-^ cells; day 1 CD138^hi^*Il10*eGFP^+^ and CD138^hi^*Il10*eGFP^-^ cells, and day 1 after re-challenge CD138^hi^*Il10*eGFP^+^ and CD138^hi^ *Il10*eGFP^-^ cells were seeded at a starting number of 10^4^ cells per well, with seven successive three-folds serial dilutions, in MultiScreenHTS IP Filter Plate (Millipore) pre-coated with anti-mouse Ig(H+L) chain (5 μg/ml; Southern Biotechnology Associates, cat number 1010-01). After 3 h incubation, plates were washed, and incubated with alkaline phosphatase-conjugated anti-IgM or total IgG or IgG1 or IgG2b or IgG2c or IgG3 or IgA overnight at 4°C (Southern Biotechnology Associates). ELISPOT were then developed using BCIP/NBT substrate.

Quantification and Statistic Analysis {#sec4.5}
-------------------------------------

Data and statistical analyses were performed using GraphPad Prism (GraphPad Software, USA) and data were represented as mean ± SEM. Equality of variances between groups was assessed before analyses by t test. Groups were compared using two-tailed t test, or Wilcoxon test, or Mann-Whitney test. t test was modified using Welch's correction in case of unequal variance (^ns^p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01; ^∗∗∗^ p \< 0.001, ^∗∗∗∗^ p \< 0.0001). No sample was excluded from analysis.

### Gene array analysis {#sec4.5.1}

Normalization of microarrays was performed using gcrma R package ([@bib36]). For each sample, we determined if a probe was present (i.e., expressed) or not using mas5calls function of affy R package ([@bib14]). The significantly differentially regulated genes were detected using limma R package ([@bib23]) with p values adjusted according to Benjamini Hochberg procedure. In order to be selected in a comparison of two conditions, each Affy IDs had to fulfill the following criteria: (i) be present in at least two of the three arrays for at least one of the two conditions compared; (ii) to have a mean signal intensity higher than 50 in at least one of the two conditions; (iii) to show an adjusted (adj.) p value \< 0.01 in the comparison of the two conditions. The genes differentially expressed between CD138^hi^*Il10*eGFP^+^ and CD138^hi^*Il10*eGFP^-^ plasmocytes (adj. p value \< 0.01) were then selected and filtered using the gene ontology resource ([www.geneontology.org](http://www.geneontology.org){#intref0330}) to focus on surface molecules. Heat-map of [Figure 1](#fig1){ref-type="fig"}A has been produced using pheatmap R package (pheatmap: Pretty Heatmaps. R package version 1.0.2. <http://CRAN.R-project.org/package=pheatmap>). If several probes were available for a given gene, their signal intensity has been averaged. For the hierarchical clustering, we used ward distance function and complete linkage function.

### DNA methylation analysis {#sec4.5.2}

Trimming, alignment to the mm10 reference genome and DNA methylation value calling were performed as described before ([@bib10]). Pairwise differential DNA methylation was calculated using the R package methylKit ([@bib1]) and DMR were defined as 1kb regions covering ≥ 3 CpG sites with ≥ 20% methylation difference (q-value ≤ 0.01) between the cell types. All analyzed CpG were filtered for coverage ≥ 10x and presence in all replicates. Average DNA methylation per cell type was calculated using coverage weighted average methylation of 3 replicates. DMR were annotated to genes and genomic location by using ChipSeek ([@bib6]). Transcription factor binding sites were predicted using TRAP ([@bib32]) and AliBaba2 (<http://gene-regulation.com/pub/programs/alibaba2/index.html>). The integrated Genome Viewer (IGV) genome browser was used to display data in [Figure 4](#fig4){ref-type="fig"}D and [Figure S4](#mmc1){ref-type="supplementary-material"}D.

### RNaseq analysis {#sec4.5.3}

Adaptor removal and trimming of low quality ends (phred score = 20) of FastQ format reads was performed using Trim Galore! (version 0.3.3) (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>). Alignment to the mm10 reference genome was done using 2-step STAR alignment ([@bib9]). PCR duplications were determined using MarkDuplicate (version 1.115) from Picard tools (<http://broadinstitute.github.io/picard/>) and quality control was performed using RNA-seQC ([@bib8]). Subsequently, featureCounts ([@bib18]) was used to count reads mapping to the genes from Gencode annotation (vM2) (<https://www.encodeproject.org/files/gencode.vM2.annotation>). Pairwise differential expression was analyzed using the R package edgeR ([@bib24]). A p value cutoff of 0.01 and an FDR cutoff of 0.05 was set to select differentially expressed genes. GO Term analysis were performed using GREAT ([@bib20]).

Data and Software Availability {#sec4.6}
------------------------------

The Affymetrix gene array data have been deposited at NCBI GEO depository and are accessible with the accession number [GSE103458](ncbi-geo:GSE103458){#intref0360}, or using the link <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103458>

The RNaseq and DNA methylation data have been deposited at the European Nucleotide Archive (ENA), and will be accessible with the accession number PRJEB22138, or using the links.<http://www.ebi.ac.uk/ena/data/view/PRJEB22138>\<https://deref-web-02.de/mail/client/dAlzMDs2lmY/dereferrer/?redirectUrl=http%3A%2F%2Fwww.ebi.ac.uk%2Fena%2Fdata%2Fview%2FPRJEB22138\>
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